News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease
ActiTrexx GmbH treats first patient with novel regulatory T cell therapy for Graft-versus-Host Disease. Phase Ib/II study evaluates safety and feasibility of Actileucel treatment -
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
Heidelberg Pharma receives USD 25 million upfront cash payment from HealthCare Royalty for royalty purchase agreement. Funds to advance ADC pipeline development and extend cash runway -
-
-
COMMUNIQUÉ DE PRESSE
INTILION receives second largest order in the company's history from energy start-up Purpel Energy
INTILION receives second largest order in the company's history from energy start-up Purpel Energy for large-scale energy storage projects in northern Germany, improving renewable energy integration and grid stability -
